Who are Treanda's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zolinza, Daunorubicin Hydrochloride, Feximac, Pepaxto, Zepzelca, Yondelis.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bendamustine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Treanda — Competitive Intelligence Brief

Treanda (BENDAMUSTINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating Drug. Area: Oncology.

marketed Alkylating Drug Histone deacetylase 6 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Treanda (BENDAMUSTINE) — Baxter. Treanda works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Treanda TARGET	BENDAMUSTINE	Baxter	marketed	Alkylating Drug	Histone deacetylase 6	2008-01-01
Zolinza	VORINOSTAT	Merck & Co.	marketed	Histone Deacetylase Inhibitor [EPC]	Histone deacetylase 6	2006-01-01
Daunorubicin Hydrochloride	daunorubicin	Meiji Seika Pharma Co., Ltd	marketed	Anthracycline Topoisomerase Inhibitor	Histone deacetylase 6	1979-01-01
Feximac	BUFEXAMAC		marketed	bufexamac	Histone deacetylase 10, Histone deacetylase 6, Arachidonate 5-lipoxygenase
Pepaxto	MELPHALAN FLUFENAMIDE	Oncopeptides Ab	marketed	Alkylating Drug		2021-01-01
Zepzelca	LURBINECTEDIN	Jazz Pharmaceuticals	marketed	Alkylating Drug [EPC]		2020-01-01
Yondelis	TRABECTEDIN	Janssen Prods	marketed	Alkylating Drug [EPC]	Proto-oncogene tyrosine-protein kinase Src	2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2032-04-25 — Pepaxto · 10285946 · US
2032-04-25 — Pepaxto · 10322182 · US
2032-04-25 — Pepaxto · 10543274 · US
2032-04-25 — Pepaxto · 10869928 · US
2032-04-25 — Pepaxto · 11344622 · US

Sponsor landscape (Alkylating Drug class)

· 1 drug in this class
Apotex · 1 drug in this class
Avet Lifesciences · 1 drug in this class
Baxter · 1 drug in this class
Eisai · 1 drug in this class
Leadiant Biosci Inc · 1 drug in this class
Oncopeptides Ab · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Treanda — Competitive Intelligence Brief. https://druglandscape.com/ci/bendamustine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab